KMS Products · 2026
Our products.
Generic dossiers, niche products, injectables and nutraceuticals developed by KMS. Each is available for licensing, co-development or supply.
01
Generic Dossiers
Generic dossiers in preparation for EU, US and rest-of-world filing. Dossier target is the month shown in the source list.
21 products
| Product | Strength · form | Therapeutic area | Market | Status |
|---|---|---|---|---|
| Semaglutide | 1.5, 3, 4, 7, 9, 14, 25 mg · Capsule | Antidiabetic | EU/US | Dossier target · Jun 2027Technology ready; pilot bio planned Oct 2026 |
| Ibuprofen | 400 mg, 600 mg · Softgel capsule | NSAID | EU/US | BE study to be doneValidation batch completed |
| Alprostadil | 0.5 mg/mL · Injection | Vasodilator | EU/US | Dossier target · Dec 2026Validation batch completed |
| Eliglustat tartrate | 84 mg · Capsule | Gaucher disease | EU | Dossier target · Jul 2027Pilot bio planned Nov 2026 |
| PivmecillinamExclusivity signed: UK | 200 mg, 400 mg · Tablet | Antibiotic | EU | Dossier target · Jul 2027Pilot bio planned Nov 2026 |
| IvermectinExclusivity signed: Netherlands, Germany, Norway, Sweden, Finland, Ukraine, Czech Republic, Australia, Denmark, Spain, UK, Poland, Austria | 1% · Cream | Antiparasitic | EU | Dossier target · Apr 2027Pilot bio completed |
| LisinoprilExclusivity signed: UK | 1 mg/mL · Oral solution | Antihypertensive | EU | Dossier target · Jun 2027Validation batch completed; planning pivotal study |
| Brimonidine tartrateExclusivity signed: UK | 0.33% · Gel | Persistent facial erythema | EU/US | Dossier target · Jul 20279-month stability completed; pilot bio planned Nov 2026 |
| Apixaban | 2.5 mg, 5 mg · Tablet | Anticoagulant | EU/US | Dossier target · Jul 2027Pilot bio planned Nov 2026 |
| Clindamycin + benzoyl peroxide | Benzoyl peroxide 2.5/3.75/5%, clindamycin phosphate 1.2/1.0% · Topical gel | Acne vulgaris | EU/US | Dossier target · Jul 2027Charged for stability |
| Sevelamer carbonate | 800 mg, 2.4 g per packet · Powder for oral suspension | Hyperphosphataemia | EU/US | Dossier target · Jul 2027Under development |
| Apremilast | 10, 20, 30 mg · Oral suspension | Immunomodulator | EU/US | Dossier target · Jul 2027Charged for stability |
| Brexpiprazole | 0.25, 0.5, 1, 2, 3, 4 mg · Tablet | Atypical antipsychotic | EU/US | Dossier target · Aug 2027Charged for stability |
| Ferric carboxymaltose | 50 mg iron/mL · Injection | Haematinic | EU/US | Dossier target · Jul 20271-year stability and characterisation completed; pilot bio planned Nov 2026 |
| Tofacitinib citrate | 11 mg, 22 mg · ER tablet | Immunomodulator | EU/US | Partner sought for dossier completionPilot bio with 1-year stability done; ready for tech transfer |
| Tofacitinib citrate | eq. 1 mg base/mL · Oral solution | Immunomodulator | EU/US | Dossier target · Aug 20279-month stability completed |
| Avibactam + ceftazidime | 0.5 g / 2 g · Injection | Antibiotic | RoW | Dossier readyDossier available for RoW markets |
| Empagliflozin + linagliptin + metformin | 25/1000, 12.5/2.5/1000, 10/1000, 5/2.5/1000 mg (as printed) · Tablet | Cardiovascular (as printed) | EU/US | Dossier target · Jul 2027Pilot bio planned Nov 2026 |
| Rifaximin | 200 mg, 550 mg · Tablet | Antibiotic | EU | Dossier target · Aug 2027Charged for stability |
| Tafluprost (preservative-free) | 0.0015% · Ophthalmic solution | Ophthalmic | EU/US | Dossier target · Jul 2027Partner sought for dossier completion |
| Oxybutynin | 2.5 mg/mL, 5 mg/mL · Oral solution | Antispasmodic | EU/US | Partner sought for dossier completionReady for technology transfer |
- SemaglutideEU/US1.5, 3, 4, 7, 9, 14, 25 mg · Capsule · AntidiabeticDossier target · Jun 2027
- IbuprofenEU/US400 mg, 600 mg · Softgel capsule · NSAIDBE study to be done
- AlprostadilEU/US0.5 mg/mL · Injection · VasodilatorDossier target · Dec 2026
- Eliglustat tartrateEU84 mg · Capsule · Gaucher diseaseDossier target · Jul 2027
- PivmecillinamEU200 mg, 400 mg · Tablet · AntibioticDossier target · Jul 2027
- IvermectinEU1% · Cream · AntiparasiticDossier target · Apr 2027
- LisinoprilEU1 mg/mL · Oral solution · AntihypertensiveDossier target · Jun 2027
- Brimonidine tartrateEU/US0.33% · Gel · Persistent facial erythemaDossier target · Jul 2027
- ApixabanEU/US2.5 mg, 5 mg · Tablet · AnticoagulantDossier target · Jul 2027
- Clindamycin + benzoyl peroxideEU/USBenzoyl peroxide 2.5/3.75/5%, clindamycin phosphate 1.2/1.0% · Topical gel · Acne vulgarisDossier target · Jul 2027
- Sevelamer carbonateEU/US800 mg, 2.4 g per packet · Powder for oral suspension · HyperphosphataemiaDossier target · Jul 2027
- ApremilastEU/US10, 20, 30 mg · Oral suspension · ImmunomodulatorDossier target · Jul 2027
- BrexpiprazoleEU/US0.25, 0.5, 1, 2, 3, 4 mg · Tablet · Atypical antipsychoticDossier target · Aug 2027
- Ferric carboxymaltoseEU/US50 mg iron/mL · Injection · HaematinicDossier target · Jul 2027
- Tofacitinib citrateEU/US11 mg, 22 mg · ER tablet · ImmunomodulatorPartner sought for dossier completion
- Tofacitinib citrateEU/USeq. 1 mg base/mL · Oral solution · ImmunomodulatorDossier target · Aug 2027
- Avibactam + ceftazidimeRoW0.5 g / 2 g · Injection · AntibioticDossier ready
- Empagliflozin + linagliptin + metforminEU/US25/1000, 12.5/2.5/1000, 10/1000, 5/2.5/1000 mg (as printed) · Tablet · Cardiovascular (as printed)Dossier target · Jul 2027
- RifaximinEU200 mg, 550 mg · Tablet · AntibioticDossier target · Aug 2027
- Tafluprost (preservative-free)EU/US0.0015% · Ophthalmic solution · OphthalmicDossier target · Jul 2027
- OxybutyninEU/US2.5 mg/mL, 5 mg/mL · Oral solution · AntispasmodicPartner sought for dossier completion
02
Niche Products
Reformulated products built on non-infringing and differentiated approaches, each shown against its reference product.
17 products
| Product | KMS formulation | Reference product | Indication | Status |
|---|---|---|---|---|
| Amlodipine | Oral solutionNon-infringing approach | Oral solution eq. 1 mg/mL | Antihypertensive (adults, children 6+) | 6-month stability completed |
| Nimodipine | Oral solutionCompetitive generic therapy approach | Oral solution 3 mg/mL, 6 mg/mL | Subarachnoid haemorrhage | Under development |
| Rosuvastatin | Oral suspension / solution | Tablets 10, 20, 40 mg | Hyperlipidaemia | 6-month stability completed |
| Solifenacin succinate | Oral suspension and solution | Tablets 5, 10 mg; oral suspension 1 mg/mL | Neurogenic detrusor overactivity (paediatric) | 6-month stability completed |
| Deferasirox | Oral suspension | Tablet for oral suspension 125, 250, 500 mg | Transfusional haemosiderosis (2 years+) | 6-month stability completed |
| Trazodone hydrochloride | Oral solution | Tablets 50, 100, 150, 300 mg | Depression and anxiety | Under development |
| Eltrombopag olamine | Ready-to-use suspension | For suspension eq. 12.5, 25 mg per sachet | Thrombocytopenia | 12-month stability completed |
| Omega-3 fatty acids | Oral solution | Suspension 1000 mg (EPA + DHA + quercetin) | Hypertriglyceridaemia | Ready for commercialisation |
| Tacrolimus | Ready-to-use injectable solutionDesign-around composition for stability | Injectable solution 5 mg/mL | Graft-rejection prevention in HSCT | Ready for technology transfer |
| Thiotepa | Ready-to-use injection | Powder for IV injection | HSCT (as printed) | Ready for technology transfer |
| Triptorelin pamoate | Ready-to-use depot injection | Powder for IM injection eq. 22.5 mg base per vial | Advanced prostate cancer (palliative) | Under development |
| Elagolix sodium | Extended-release tabletNon-infringing approach | Tablet eq. 150, 200 mg base | Endometriosis pain (moderate to severe) | Under development |
| Sucroferric oxyhydroxide | Tablet (differentiated) | Tablet 500 mg | Hyperphosphataemia in CKD | Ready for technology transfer |
| Rimegepant sulfate | Tablet (differentiated) | Orally disintegrating tablet eq. 75 mg base | Migraine (acute treatment) | Under development |
| Gabapentin | Cream | Capsule 100, 200 mg; tablet 300–800 mg; oral solution 250 mg/5 mL | Neuropathic pain | POC established / under development |
| Doxepin | Oral liquid (dose reduction) | Oral concentrate eq. 10 mg base/mL | Major depressive disorder | POC established / under development |
| Dapsone | Topical gel (differentiated) | Topical gel 5%, 7.5% | Acne vulgaris | POC established / under development |
- AmlodipineOral solution · Antihypertensive (adults, children 6+)6-month stability completed
- NimodipineOral solution · Subarachnoid haemorrhageUnder development
- RosuvastatinOral suspension / solution · Hyperlipidaemia6-month stability completed
- Solifenacin succinateOral suspension and solution · Neurogenic detrusor overactivity (paediatric)6-month stability completed
- DeferasiroxOral suspension · Transfusional haemosiderosis (2 years+)6-month stability completed
- Trazodone hydrochlorideOral solution · Depression and anxietyUnder development
- Eltrombopag olamineReady-to-use suspension · Thrombocytopenia12-month stability completed
- Omega-3 fatty acidsOral solution · HypertriglyceridaemiaReady for commercialisation
- TacrolimusReady-to-use injectable solution · Graft-rejection prevention in HSCTReady for technology transfer
- ThiotepaReady-to-use injection · HSCT (as printed)Ready for technology transfer
- Triptorelin pamoateReady-to-use depot injection · Advanced prostate cancer (palliative)Under development
- Elagolix sodiumExtended-release tablet · Endometriosis pain (moderate to severe)Under development
- Sucroferric oxyhydroxideTablet (differentiated) · Hyperphosphataemia in CKDReady for technology transfer
- Rimegepant sulfateTablet (differentiated) · Migraine (acute treatment)Under development
- GabapentinCream · Neuropathic painPOC established / under development
- DoxepinOral liquid (dose reduction) · Major depressive disorderPOC established / under development
- DapsoneTopical gel (differentiated) · Acne vulgarisPOC established / under development
03
Injectables
Injectable products in development and ready for technology transfer.
5 products
Alprostadil
0.5 mg/mL · Injection
Vasodilator
Exhibit batch completed; dossier ready by Oct 2026
Ferric carboxymaltose
50 mg iron/mL · Injection
Haematinic
Prototype completed; dossier ready by Dec 2026
Thiotepa
5 mg/mL · Powder for IV injection
Graft-rejection prevention in HSCT
Ready for technology transfer
Triptorelin pamoate RTU
1.875 mg/mL · Ready-to-use injection
Advanced prostate cancer (palliative)
Under development
Triptorelin pamoate
eq. 22.5 mg base per vial · Powder for IM injection
Advanced prostate cancer (palliative)
Under development
04
Nutraceuticals
Nutraceutical and wellness products available for partnering.
25 products
Narpega S
Soft gelatin capsule
Heart health · omega-3
Narpega L
Oral micro-emulsion
Heart health · omega-3
Narpega CS
Hard gel capsule
Lipid and heart health
Narpega CD S
Capsule
Heart health and overall wellness
KMS Curcupi
Oral soluble tablet
Curcumin supplementation
KMS Curcupi-D
Tablet
Immunity, bone and joint health
AFLD
Tablet
Fatty liver disease (NAFLD)
Drypsin
Tablet
Pain, sprains, strains and trauma
Nutrivas
Tablet
Vascular health · Lp(a) in dyslipidaemia
LoHbA1c
Tablet
Diabetes management
Mepal
Tablet
Diabetic neuropathy
S-Gen
Tablet
Male fertility
VB Cap
Capsule (oral probiotic)
Vaginal health
Cramnil-T
Capsule
Cramps, muscle fatigue and bone health
Cramnil-G
Gel
Muscle spasm and recovery
KMSAC
Sachet
Urinary calculi, UTI and burning micturition
Halitoshield
Tablet
Instant mouth freshness
Ilivemet
Sugar-coated tablet
Liver health
Immunbooster
Chewable tablet
Immunity
V-Gel
Intimate care gel
Vulvitis and balanitis
Gynocare T
Tablet
Pregnancy nutrition
Ibsease
Enteric-coated capsule
Irritable bowel syndrome
DHA Powder
Powder
Brain development and cognition
KMS Spirulina
Powder
Everyday nutrition
Curcumin Latte
Powder (drink mix)
Everyday wellness
Source: KMS Product List 2026 (version 19), KMS Niche Product List 2026 (version 5), KMS Injectable Product List and KMS Nutraceutical Presentation.V-20 For product information or licensing, write to vasanthi@kmshc.com or ganesan@kmshc.com.
Ways to partner
Five ways to engage, one team behind each.
01
Dossier development
We develop the product and the dossier; you file it.
02
Dossier compilation
We turn development data you already hold into a submission-ready dossier.
03
Co-development
We share the development investment and the commercial return through profit sharing.
04
Technology transfer
We move a developed product into your plant or your chosen CMO.
05
Commercial supply
We supply finished product through a qualified manufacturing network.
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · ganesan@kmshc.com · +91 97898 75194V-23